Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors

Steroids

Volumn 73, Issue 14, 2008, Pages 1409-1415

  Cepa, Margarida M D S ^a,b   Tavares da Silva, Elisiário J ^c   Correia da Silva, Georgina ^a,b   Roleira, Fernanda M F ^c   Teixeira, Natércia A A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Aromatase inhibitor; Breast cancer; Structure function study; Synthetic androstanes

Indexed keywords

3,4 EPOXYANDROSTANE; 3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17 ONE; 3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17 ONE OXIME; 3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17BETA OL; 3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17BETA YL ACETATE; 5ALPHA ANDROST 3 EN 17 ONE; 5ALPHA ANDROST 3 EN 17 ONE OXIME; 5ALPHA ANDROST 3 EN 17BETA OL; 5ALPHA ANDROST 3 EN 17BETA YL ACETATE; AROMATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; CHEMICAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; KINETICS;

ANDROSTENES; AROMATASE; AROMATASE INHIBITORS; FEMALE; HUMANS; KINETICS; MICROSOMES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLACENTA; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55549118561     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.07.001     Document Type: Article

References (22)

1. Cuzick J., Wang D.Y., and Bulbrook R.D. The prevention of breast cancer. Lancet 8472 (1986) 83-86
2. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
3. Perez E.A. Appraising adjuvant aromatase inhibitor therapy. Oncologist 11 (2006) 1058-1069
4. Thuerlimann B., Koeberle D., and Senn H. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. Eur J Cancer 43 (2007) 46-52
5. Jordan V.C., and Brodie A. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 (2007) 7-25
6. Howell A., and Buzdar A. Are aromatase inhibitors superior to antiestrogens?. J Steroid Biochem Mol Biol 93 (2005) 237-247
7. O'Reillly J.M., and Brueggmeier R.W. Development of steroidal and non-steroidal inhibitors of aromatase for the treatment of hormone-dependent breast cancer. Curr Med Chem 3 (1996) 11-22
8. Banting L., Nicholls P.J., Shaw M.A., and Smith H.J. Recent developments in aromatase inhibition as a potential treatment for estrogen-dependent breast cancer. Prog Med Chem 26 (1989) 253-298
9. Banting L. Inhibition of aromatase. Prog Med Chem 33 (1996) 147-184
10. Miller W.R., Anderson T.J., and Jack W.J.L. Relationship between tumor aromatase activity, tumor characteristics and response to therapy. J Steroid Biochem Mol Biol 37 (1990) 537-548
11. Cepa M.M.D.S., Tavares da Silva E.J., Correia-da-Silva G., Roleira F.M.F., and Teixeira N.A.A. Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: Design, synthesis and biological activity evaluation. J Med Chem 48 (2005) 6379-6385
12. Sherwin P.F., McMullan P.C., and Covey D.F. Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. J Med Chem 32 (1989) 651-658
13. Numazawa M., Kamiyama T., Tachibana M., and Oshibe M.J. Synthesis and structure-activity relationships of 6-substituted androst-4-ene analogs as aromatase inhibitors. J Med Chem 39 (1996) 2245-2252
14. Rasmusson G.H. In: Fried J.H., and Edwards J.A. (Eds). Organic reactions in steroid chemistry vol. I (1972), Van Nostrand-Reinhold, New York 222-264
15. McKenna J., Norymbersky J.K., and Stubbs R.D. Partial reduction of steroid hormones and related substances. Part III. The reaction of α,β-unsaturated ketones with zinc in acetic acid. J Chem Soc (1959) 2502-2509
16. Yoshida N., and Osawa Y. Purification of human placental aromatase cytocrome P-450 with monoclonal antibody and its characterization. Biochemistry 30 (1991) 3003-3010
17. Thompson E.A., and Siiteri P.K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. Biol Chem 249 (1974) 53-64
18. Heidrich D., Steckelbroeck S., and Klingmuller D. Inhibiton of human cytocrome P-450 aromatase activity by butylins. Steroids 66 (2001) 763-769
19. Favia A.D., Cavalli A., Masetti M., Carotti A., and Recanatini M. Three-dimensional modal of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62 (2006) 1074-1087
20. Hong Y., Yu B., Sherman M., Yuan Y.C., Zhou D., and Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 21 (2007) 401-414
21. Oh S.S., and Robinson C.H. Mechanism of human placental aromatase: a new active site model. J Steroid Biochem Mol Biol 44 (1993) 389-397
22. Graham-Lorence S., Amarneh B., White R.E., Peterson J.A., and Simpson E.R. A three-dimensional model of aromatase cytochrome P450. Protein Sci 4 (1995) 1065-1080